You have a valid point on past studies on 2mg. The purpose of the P3 study design was to determine lowest effective dose hence the stage gate approach. 2mg x2 studies set the benchmark (threshold) for both PAR and FDA. Ironically It actually mitigates our risk BUT also translates into extra cost and time.
You have a valid point on past studies on 2mg. The purpose of...
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
0.010(4.26%) |
Mkt cap ! $83.95M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 24.5¢ | 23.5¢ | $75.52K | 315.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 64737 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 30757 | 4 |
View Market Depth
| Last trade - 12.35pm 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
24.5¢ |
Change
0.010 ( 4.26 %) |
||||
| Open | High | Low | Volume | ||
| 24.0¢ | 25.0¢ | 23.5¢ | 80731 | ||
| Last updated 12.54pm 07/05/2024 ? | |||||
| PAR (ASX) Chart |